High response rates for stage 1-II indolent B-cell lymphoma with yttrium-90 ibritumomab tiuxetan (Zevalin)

被引：0
|
作者：
Samaniego, F. [1 ]
Pro, B. [1 ]
Nunez, R. [1 ]
McLaughlin, P. [1 ]
Fanale, M. [1 ]
Kwak, L. [1 ]
Romaguera, J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [41] The use of Yttrium-90 Ibritumomab Tiuxetan (Y-90-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation
    Jurczak, Wojciech
    Kisiel, Elzbieta
    Sawczuk-Chabin, Joanna
    Centkowski, Piotr
    Knopinska-Posluszny, Wanda
    Khan, Omeir
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2015, 19 (01): : 43 - 47
  • [42] IBRITUMOMAB TIUXETAN (ZEVALIN®) IS HIGHLY EFFECTIVE IN FIRST RELAPSED INDOLENT B CELL NON-HODGKIN LYMPHOMA (B-NHL)
    Uchida, Toshiki
    Suzuki, Tatsuya
    Oyama, Takashi
    Okamoto, Akinao
    Kasai, Masanobu
    Ikeda, Mika
    Nanbu, Ichiro
    Nakamura, Masashi
    Imamura, Shin
    Ogura, Michinori
    ANNALS OF ONCOLOGY, 2010, 21 : 39 - 39
  • [43] Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study
    Ilseung Choi
    Masaya Okada
    Tomoki Ito
    Annals of Hematology, 2023, 102 : 1149 - 1158
  • [44] Yttrium-90 ibritumomab tiuxetan combined with high-dose beam chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Scheid, C.
    Huebel, K.
    Boldt, F.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 241 - 242
  • [45] Yttrium-90 ibritumomab tiuxetan combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Huebel, K.
    Scheid, C.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study
    Choi, Ilseung
    Okada, Masaya
    Ito, Tomoki
    ANNALS OF HEMATOLOGY, 2023, 102 (05) : 1149 - 1158
  • [47] Phase II Study of 2-Weekly CHOP plus Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis
    Karmali, Reem
    Manson, Andrew
    Bueschel, Katherine
    Shell, Kathryn
    Gregory, Stephanie A.
    O'Brien, Teresa
    Shammo, Jamile M.
    Larson, Melissa L.
    Venugopal, Parmeswaran
    BLOOD, 2010, 116 (21) : 1609 - 1610
  • [48] Yttrium-90 -: ibritumomab tiuxetan (Zevalin®) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin lymphoma
    Shimoni, A.
    Zwas, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Avigdor, A.
    Ben-Bassat, I.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S145 - S145
  • [49] Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).
    Hamlin, Paul A., Jr.
    Rodriguez, Maria Alma
    Noy, Ariela
    Portlock, Carol S.
    Straus, David
    McLaughlin, Peter
    Pro, Barbara
    Fayad, Luis
    Hagemeister, Frederick
    Wegner, Brett
    Dumitrescu, Otilia
    Tasker, Neetha Pandit
    Moskowitz, Craig H.
    Zelenetz, Andrew D.
    BLOOD, 2010, 116 (21) : 748 - 749
  • [50] Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma
    Othman, Tamer
    Lowsky, Robert
    Richman, Carol
    Hoeg, Rasmus
    Abedi, Mehrdad
    Tuscano, Joseph
    BONE MARROW TRANSPLANTATION, 2023, 58 (10) : 1143 - 1145
12345